Vital Signs
Revolution Medicines reported phase 3 data showing its once-daily RAS inhibitor daraxonrasib extended median overall survival to 13.2 months in patients with previously treated metastatic pancreatic ductal adenocarcinoma, compared to 6.7 months on standard chemotherapy—a 60% reduction in death risk at interim analysis. This marks a rare win in a field starved for progress, where second-line options have historically offered mere months of benefit and five-year survival hovers below 10%; the drug's 55% response rate in earlier trials fueled high expectations, now validated in roughly 400 patients.
Biotech analysts called the results "dramatic and practice-changing," with Revolution's stock surging over 40% as the company accelerates toward regulatory filings later this year. Targeting the notoriously tricky RAS mutations driving nearly all pancreatic cancers, daraxonrasib builds on years of oncology advances, positioning it as a potential new standard where chemo toxicity often limits use—observers on platforms like X echoed the urgency, noting it could reach patients "who urgently need new treatment."
A 63-year-old Norwegian man, dubbed the "Oslo patient," remains HIV-free more than five years after a 2019 stem cell transplant from his brother, who carries two copies of the rare CCR5Δ32 mutation that blocks HIV entry into cells—no viral rebound detected across blood, bone marrow, gut tissues, or lab-cultured immune cells after stopping antiretrovirals 24 months post-transplant. Diagnosed in 2006 and later treated for myelodysplastic syndrome, his case—detailed in Nature Microbiology—is the first documented cure using a genetically related donor, adding to about seven to ten similar remissions worldwide from high-risk procedures originally for blood cancers.
Experts like Dr. Marius Trøseid hailed it as "valuable evidence" strengthening cure research, though they stressed its rarity—a perfect sibling match combines a 25% HLA compatibility chance with the mutation's 1% prevalence in northern Europeans—ruling out scalability for 30+ million HIV cases. Social media buzz focused on the milestone's inspiration for functional cures like engineered antibodies, with researchers noting full immune replacement by donor cells as key to reservoir clearance.
The FDA fully approved Travere Therapeutics' Filspari (sparsentan), a dual endothelin/angiotensin receptor antagonist, for focal segmental glomerulosclerosis (FSGS), a scarring kidney disorder affecting roughly 40,000 U.S. adults with no prior approved treatments—label expansion from its accelerated nod for IgA nephropathy, backed by phase 3 data showing superior proteinuria reduction. FSGS often leads to dialysis or transplant in young patients, making this oral therapy's immediate availability via Travere's support program a critical step forward after years of failed trials in the space.
Industry reactions highlighted the milestone's revenue potential at twice the IgAN dose, with Ligand Pharmaceuticals noting boosted royalties; biotech watchers on X celebrated it as a "new revenue stream" for the ~5,000 annual U.S. diagnoses, underscoring Filspari's role in addressing unmet needs in glomerular diseases.
Researchers at UT Austin and Metagenomi engineered Al3Cas12f RKK, a hypercompact CRISPR enzyme small enough for adeno-associated virus delivery, achieving over 80-90% gene-editing efficiency in human cells and mice for targets linked to cancer, heart disease, and ALS—vaulting past the original's under 10% by optimizing structure for in vivo use. This miniaturization solves a key bottleneck in gene therapies, where larger Cas proteins exceed AAV cargo limits, potentially broadening access to treatments for hard-to-reach tissues.
Published amid surging CRISPR trials, the advance drew praise for paving "doors for therapeutic genome editing," with early X discussions tying it to NIH-funded efforts expanding options beyond ex vivo editing.
In an early cut from the phase 2 ALPHA3 trial, Allogene Therapeutics' allogeneic CAR-T cema-cel eliminated all detectable minimal residual disease in more than 50% of large B-cell lymphoma patients post-chemoimmunotherapy—a 42% absolute improvement over expectations and three times better than controls—hinting at relapse prevention in first-line consolidation. Unlike patient-specific autologous CAR-Ts plagued by manufacturing delays, this off-the-shelf approach promises rapid access, with enrollment wrapping by 2027.
Biopharma analysts and X observers lauded the safety profile and MRD clearance as "incredible" validation for scalable cell therapy, sending shares up 25% amid 2026 catalysts for oncology and autoimmunity.